Treatment characteristics and outcomes of patients with MDS on HMAs
| Treatment characteristics . | Any HMA, n (%) . | Azacitidine, n (%) . | Decitabine, n (%) . |
|---|---|---|---|
| On the following treatments before HMA, n (%) | |||
| ESA | 2183 (27.5) | 1695 (29.2) | 488 (22.8) |
| Lenalidomide | 208 (2.6) | 158 (2.7) | 50 (2.3) |
| G-CSF or GM-CSF | 692 (8.7) | 479 (8.3) | 213 (10) |
| TPO-R, danazol, or high-intensity chemotherapy | 88 (1.1) | 59 (1) | 29 (1.4) |
| On HMA at the following treatment period, n (%) | |||
| Fourth treatment period | 5109 (64.4) | 3821 (65.9) | 1288 (60.2) |
| Received complete cycles in all first 4 treatment periods | 2520 (31.7) | 1952 (51.1) | 568 (44.1) |
| Sixth treatment period | 3980 (50.1) | 2972 (51.3) | 1008 (47.1) |
| Received complete cycles in all first 6 treatment periods | 1548 (19.5) | 1217 (40.9) | 331 (32.8) |
| Events within 90 days after the last index HMA treatment, n (%) | |||
| Switched to the other HMA | 721 (9.1) | 570 (9.8) | 151 (7.1) |
| Death | 3077 (38.8) | 2162 (37.3) | 915 (42.8) |
| Diagnosed with AML | 3245 (40.9) | 2176 (37.5) | 1069 (50) |
| Proceeded to bone marrow transplant | 235 (2.9) | 165 (2.8) | 70 (3.3) |
| Had high-intensity chemotherapy | 80 (1) | 51 (0.9) | 29 (1.4) |
| Treatment characteristics . | Any HMA, n (%) . | Azacitidine, n (%) . | Decitabine, n (%) . |
|---|---|---|---|
| On the following treatments before HMA, n (%) | |||
| ESA | 2183 (27.5) | 1695 (29.2) | 488 (22.8) |
| Lenalidomide | 208 (2.6) | 158 (2.7) | 50 (2.3) |
| G-CSF or GM-CSF | 692 (8.7) | 479 (8.3) | 213 (10) |
| TPO-R, danazol, or high-intensity chemotherapy | 88 (1.1) | 59 (1) | 29 (1.4) |
| On HMA at the following treatment period, n (%) | |||
| Fourth treatment period | 5109 (64.4) | 3821 (65.9) | 1288 (60.2) |
| Received complete cycles in all first 4 treatment periods | 2520 (31.7) | 1952 (51.1) | 568 (44.1) |
| Sixth treatment period | 3980 (50.1) | 2972 (51.3) | 1008 (47.1) |
| Received complete cycles in all first 6 treatment periods | 1548 (19.5) | 1217 (40.9) | 331 (32.8) |
| Events within 90 days after the last index HMA treatment, n (%) | |||
| Switched to the other HMA | 721 (9.1) | 570 (9.8) | 151 (7.1) |
| Death | 3077 (38.8) | 2162 (37.3) | 915 (42.8) |
| Diagnosed with AML | 3245 (40.9) | 2176 (37.5) | 1069 (50) |
| Proceeded to bone marrow transplant | 235 (2.9) | 165 (2.8) | 70 (3.3) |
| Had high-intensity chemotherapy | 80 (1) | 51 (0.9) | 29 (1.4) |
AML, acute myeloid leukemia; ESA, erythropoiesis stimulating agents; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte monocyte colony-stimulating factor; TPO-R, thrombopoietin-receptor agonists.